NCT06122584招募中3 期
Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 380
- 试验地点
- 29
- 主要终点
- Sensitivity and specificity of [18F]PSMA-1007 PET/CT for the detection of pelvic nodal disease (N1) compared to histology as the standard of reference
研究概览
简要总结
This study assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •The patient (male) is aged 18 years or above.
- •The patient is able to understand the information presented to him concerning the nature, scope, and consequences of the trial as set out in the information provided to the patient AND has provided written informed consent to participate.
- •The patient has newly diagnosed, biopsy-proven, clinically localized prostate adenocarcinoma, and curative prostatectomy with extended pelvic lymph node dissection is his preferred course of treatment.
- •The patient has at least high-risk disease as defined by the NCCN guidelines (version 1.2023). That is, the presence of any one or more of the following:
- •Overall ISUP grade group 4 or 5,
- •Clinical category T3a or greater,
- •Serum PSA level greater than 20 ng/ml.
- •The patient has undergone conventional imaging (CT or MRI, and bone scan if clinically indicated) to detect the presence of pelvic nodal involvement and bone or visceral metastases within 60 days of the planned PET-CT procedure.
排除标准
- •Patients for whom radical prostatectomy is not clinically appropriate or the patient is otherwise unlikely to undergo radical prostatectomy with extensive pelvic lymph node dissection.
- •The patient has received any therapy - be it radiation, surgical or drug therapy - for his prostate cancer.
- •The patient has any contraindication(s) for and/or known hypersensitivity to any constituent(s) of [18F]PSMA-
- •The patient is not able to have PET-CT scans (for example, because of weight, claustrophobia, or inability to lie still for the duration of the scan).
- •The patient is closely affiliated to the investigation site; e.g. is a first-degree relative of the investigator.
- •At the time of screening, the patient is receiving any other investigational agent(s), or he has received any such agent(s) within the previous 30 days, or he is scheduled to receive any such agent(s) in the period up to the planned date for the last study visit.
- •The patient has previously been enrolled in this trial.
- •The patient has previously undergone PET imaging with any PSMA-avid product.
- •The patient has histological evidence of small-cell carcinoma of the prostate.
- •The patient is clinically unstable or requires emergency treatment.
- •The patient has any mental condition rendering him incapable of understanding the nature, scope, and consequences of the trial as set out in the information given to the patient.
研究组 & 干预措施
[18F]PSMA-1007
Experimental
Single intravenous administration of [18F]PSMA-1007 for Positron Emission Tomography (PET) scan
干预措施: [18F]PSMA-1007 (Drug)
结局指标
主要结局
Sensitivity and specificity of [18F]PSMA-1007 PET/CT for the detection of pelvic nodal disease (N1) compared to histology as the standard of reference
时间窗: 6 to 8 weeks post-surgery
次要结局
未报告次要终点
研究者
研究点 (29)
Loading locations...
相似试验
已完成
3 期
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate CancerProstate Cancer RecurrentProstate CancerNCT04742361ABX advanced biochemical compounds GmbH136
已完成
不适用
Clinical utility of [F-18]PSMA-1007 PET/CT (positron emission tomography/computed tomography) in evaluating preoperative staging of prostate cancer before radical prostatectomyKCT0004476Yonsei University Health System, Severance Hospital126
终止
不适用
PSMA-PET/CT RegistryProstate CancerNCT05709535AHS Cancer Control Alberta128
已完成
1 期
An Open-label, Single-arm, Rater-blinded, Multicenter Phase 1/2 Study to Assess Safety and Diagnostic Accuracy and Radiotherapeutic Implications of Pre-operative Ga-68-PSMA-11 PET/CT Imaging in Comparison to Histopathology, in Newly-diagnosed Prostate Cancer (PCA) Patients at High Risk for Metastasis, Scheduled for Radical Prostatectomy (RP) With Extended Pelvic Lymph Node Dissection (EPLND)High-risk Prostate CancerProstate Cancer MetastaticLymphnode MetastasisC61Malignant neoplasm of prostateDRKS00013701Deutsches Krebsforschungszentrum (DKFZ) Heidelberg173
进行中（未招募）
2 期
18F-PSMA-1007 PET/CT Imaging in Patients With Biochemically Recurrent or High-risk Prostate CancerProstate CancerNCT04733768University of Alberta100